Celltrion’s biosimilar ‘Herzuma’ proven in equivalence of efficacy with original

At the European Society for Medical Oncology(ESMO) symposium on the 9^th(local time) in Madrid, Spain, Celltrion announced additional clinical trial results of 1-year safety of Herzuma(development name: CT-P6), an antibody biosimilar for the treatment of breast cancer, on early breast cancer patients.

Herzuma, an antibody biosimilar used to treat breast cancer and stomach cancer, references ‘He...